This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

EU Pharmaceutical Law Forum
Hybrid Event | 23 - 25 May 2023
Steigenberger Wiltcher's, Brussels

Alexander Roussanov
Partner at Arnold & Porter


Alexander Roussanov, a former senior legal adviser in the Legal Department of the European Medicines Agency (EMA), focuses his practice on a broad range of issues related to the life-cycle of medicinal products and medical devices. His experience includes product classification, authorization and conduct of clinical trials for medicinal products and clinical investigations for medical devices, marketing authorization for medicinal products and CE marking of medical devices, pharmacovigilance and device vigilance, marketing and promotion activities, privacy and data protection counseling, and interactions with health care professionals.

He is well-versed in certain EMA-specific regulations, including those surrounding advanced therapy medicinal products, marketing authorization procedures, referral procedures, GxP inspections, the Agency's freedom of information policy and clinical data transparency. In addition, he has represented the EMA in litigation in the Court of Justice of the European Union.

Mr. Roussanov advises clients on the form and terms of various types of agreements important for the efficient conduct of research activities including clinical study agreements, sponsor's representative agreements, registry agreements and CRO agreements. He also has experience in internal investigations, audits and regulatory due-diligence projects.

He has extensive practical experience counseling organizations on data security and privacy matters. Mr. Roussanov has assisted clients with compliance requirements of Regulation (EU) 2016/679 (GDPR). He advises on many aspects of the GDPR that are of particular importance in the Life Sciences sector. These include the collection and processing of patients' personal health data and genetic data, transfer of personal health data outside the EU and the territorial scope of the GDPR.

Agenda Sessions

  • DUAL DIALOGUE: Concerns and Conflicts Surrounding the Secondary Use of Clinical Research Data


Speakers at this event